Roche is a global healthcare company based in Basel, Switzerland, that specializes in pharmaceuticals and diagnostics. It focuses on improving patient outcomes through innovative medicines and diagnostic solutions. Roche's pharmaceutical division provides a wide range of treatments for various medical conditions, including oncology, virology, and inflammation, with well-known products such as Avastin, Herceptin, and MabThera. The diagnostics division offers comprehensive in-vitro diagnostic tests and systems, playing a crucial role in early disease detection, monitoring, and research. Roche Molecular Systems develops and commercializes diagnostic tests employing advanced PCR technologies for virology, blood screening, and oncology. Additionally, the Roche Venture Fund invests in early-stage life science companies, supporting innovations in biotechnology and diagnostics with a portfolio that spans multiple countries. Through these initiatives, Roche continues to enhance healthcare solutions worldwide while committing to significant investments in research and development.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. Trophos is a fully integrated clinical stage company with a pipeline of original molecules in development for the motoneuron diseases amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and spinal muscular atrophy (SMA), chemotherapy-induced peripheral neuropathy, cardiac ischemia-reperfusion injury and other neurological conditions.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Therapeutic Human Polyclonals
Acquisition in 2007
THP is an emerging biotechnology company focused on research in the field of human antibody technologies. THP has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy.